+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Xerostomia - Pipeline Review, H2 2019

  • ID: 4861681
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 37 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Capricor Therapeutics Inc
  • Humanetics Corp
  • Icure Pharmaceutical Inc
  • Lubris Biopharma
  • MeiraGTx Holdings Plc
  • MyX Therapeutics Inc
  • MORE
Xerostomia - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Xerostomia - Pipeline Review, H2 2019, provides an overview of the Xerostomia (Mouth and Dental Disorders) pipeline landscape.

Xerostomia is defined as dry mouth resulting from reduced saliva flow. It is caused by medications, age, cancer treatment, injury, dehydration and chewing or smoking tobacco. Symptoms include dysgeusia, fungal infections, bad breath, tongue ulcers, problems speaking and sticky saliva. Treatment includes medications which stimulating saliva production.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Xerostomia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Xerostomia (Mouth and Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Xerostomia (Mouth and Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Xerostomia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 1 and 1 respectively.

Xerostomia (Mouth and Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Xerostomia (Mouth and Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Xerostomia (Mouth and Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Xerostomia (Mouth and Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Xerostomia (Mouth and Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Xerostomia (Mouth and Dental Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Xerostomia (Mouth and Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Xerostomia (Mouth and Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Capricor Therapeutics Inc
  • Humanetics Corp
  • Icure Pharmaceutical Inc
  • Lubris Biopharma
  • MeiraGTx Holdings Plc
  • MyX Therapeutics Inc
  • MORE
Introduction
Report Coverage
Xerostomia - Overview
Xerostomia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Xerostomia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Xerostomia - Companies Involved in Therapeutics Development
BioCurity Pharmaceuticals Inc
Capricor Therapeutics Inc
Humanetics Corp
Icure Pharmaceutical Inc
Lubris Biopharma
MeiraGTx Holdings Plc
MyX Therapeutics Inc
Xerostomia - Drug Profiles
A-00X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAP-2003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerium oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Xerostomia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, and Xerostomia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genistein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBS-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pilocarpine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xerostomia - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Xerostomia, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Xerostomia - Pipeline by BioCurity Pharmaceuticals Inc, H2 2019
Xerostomia - Pipeline by Capricor Therapeutics Inc, H2 2019
Xerostomia - Pipeline by Humanetics Corp, H2 2019
Xerostomia - Pipeline by Icure Pharmaceutical Inc, H2 2019
Xerostomia - Pipeline by Lubris Biopharma, H2 2019
Xerostomia - Pipeline by MeiraGTx Holdings Plc, H2 2019
Xerostomia - Pipeline by MyX Therapeutics Inc, H2 2019
Xerostomia - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Xerostomia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • BioCurity Pharmaceuticals Inc
  • Capricor Therapeutics Inc
  • Humanetics Corp
  • Icure Pharmaceutical Inc
  • Lubris Biopharma
  • MeiraGTx Holdings Plc
  • MyX Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll